Capability
OxVax: Pioneering Off‑the‑Shelf Dendritic Cell Vaccines
How does OxVax's off-the-shelf dendritic-cell vaccine platform (CD141+ cells from iPSC) enable bulk immunotherapy manufacture?
OxVax Ltd is an Oxford-based immuno-oncology spin-off developing an off-the-shelf cancer vaccine. Defence-finance analysis; 39-page sourced DFM PDF report.
This public thread presents the concise analytical answer. The complete evidence, source base and assessment are available below.
Part of our Research, Universities & Deep Tech and Defence & Dual-Use Companies coverage →
Original DFM publication · DFM Analysis report · 2025-08-18
OxVax Ltd is an Oxford-based immuno-oncology spin-off developing an off-the-shelf cancer vaccine platform built on a proprietary subset of dendritic cells.
This emerging biotech venture has its roots in the University of Oxford’s Sir William Dunn School of Pathology, where its founding scientists discovered how to generate CD141⁺ dendritic cells from induced pluripotent stem cells (iPSC) – a breakthrough enabling bulk manufacture of potent antigen-presenting cells for immunotherapy.
This analysis answers: How does OxVax's off-the-shelf dendritic-cell vaccine platform (CD141+ cells from iPSC) enable bulk immunotherapy manufacture? What is the maturity of this University of Oxford (Dunn School) spin-off's technology? Which immuno-oncology partners, markets and dual-use health-security applications does OxVax target? What capability gaps or dependencies affect scaling its proprietary dendritic-cell manufacturing?
Choose how to continue
Go deeper on this question
Full sourced report
OxVax: Pioneering Off‑the‑Shelf Dendritic Cell Vaccines
View the report →
Keep getting the analysis
DFM publishes new analysis on Microelectronics, Quantum & Biotechnology every week.
Original DFM analysis
OxVax: Pioneering Off‑the‑Shelf Dendritic Cell Vaccines
The publication details above identify the source used for this public thread.
FAQ
What is OxVax: Pioneering Off‑the‑Shelf Dendritic Cell Vaccines?
This emerging biotech venture has its roots in the University of Oxford’s Sir William Dunn School of Pathology, where its founding scientists discovered how to generate CD141⁺ dendritic cells from induced pluripotent…
Related DFM Platform threads
Explore this category Strategic Autonomy
Professional requests (internal interest signal — not a marketplace; nothing is charged or promised)
See Professional & Institutional Access — plans, group/institutional seats and contact →
Defence Finance Monitor is an analytical and informational product. It does not constitute investment advice, financial advice or a recommendation to buy or sell securities. Subscriptions run on DFM Analysis. Payments for Professional Packs are processed securely by Stripe at checkout.